跳至主要内容
临床试验/NCT03713437
NCT03713437已完成不适用

Measurement of Beta Cell Death in Individuals With Cystic Fibrosis

University of Nebraska1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2019年4月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
Levels of differentially methylated insulin DNA from infancy to early adulthood in people with cystic fibrosis

研究概览

简要总结

This study evaluates the feasibility of using differentially methylated insulin DNA, a biomarker of beta cell death, in determining the time course of beta cell death and development of diabetes in people with cystic fibrosis. Study participants with cystic fibrosis and healthy control participants will have a blood sample drawn in order to measure the levels of differentially methylated insulin DNA.

详细描述

Cystic fibrosis related diabetes (CFRD) causes increased morbidity and mortality in people with cystic fibrosis (CF). The prevalence of CFRD increases with age. While CFRD is diagnosed in only 2 percent of children under 10 year sof age, it is present in 19 percent of adolescents and up to 50 percent of adults with CF. Although CFRD is uncommon in children, recent animal and human studies have shown that milder glycemic abnormalities are common in infants and young children with CF. One of the proposed mechanisms for early glucose dysregulation in CF is related to ongoing beta cell death that may start at a very early age. The assay to be used in this study measures differentially methylated insulin DNA, released exclusively by beta cells, to determine levels of beta cell death. This assay has been shown to detect beta cell death in individuals at risk of developing type 1 diabetes. If this assay successfully detects beta cell death in individuals with CF, the investigators can identify critical time points of beta cell loss in people with CF. Understanding how and when glycemic dysregulation occurs in CF will lead to better treatment of CFRD in the future.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
— 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Levels of differentially methylated insulin DNA from infancy to early adulthood in people with cystic fibrosis

时间窗: Level to be drawn once, usually within 3 months of recruitment into study.

Levels of differentially methylated insulin DNA in people with CF from infancy to young adulthood will be measured and compared to levels in healthy, age-matched controls.

次要结局

  • Correlation between level of differentially methylated insulin DNA and use of CFTR modulator therapy.(Level to be drawn once, usually within 3 months of recruitment into study.)
  • Correlation between level of differentially methylated insulin DNA and oral glucose tolerance status in people with CF.(Level to be drawn once, usually within 3 months of recruitment into study.)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验